Introduction
Lymphangioleiomyomatosis is a rare disease (1/1,000,000) with multisystemic involvement, that occurs mainly in female individuals in the 4th decade of life. It is usually associated with tuberous sclerosis complex (TSC). When isolated it is called sporadic lymphangioleiomyomatosis (LAM) and lacks the skin manifestations (e.g., fibromas, facial angiofibromas, hypomelanotic macules). The primary affected organ of sporadic LAM is the lung (bilateral thin-walled cysts in chest-computed tomography (CT)). Extra-pulmonary LAM is rarer, involving lesions of the lymphatic vasculature (chylothorax, chylous ascites and lymph node lymphangioleiomyomatosis) and renal angiomyolipomas (AMLs). Lymphadenopathy, especially retroperitoneal and pelvic, is not uncommon in patients with pulmonary LAM, but no study has specifically examined the prognostic significance of small, incidental LAM occasionally identified in lymph nodes resected for unrelated purposes.1-5

Case Report
We report the case of a 48-year-old female patient with history of arterial hypertension and dyslipidemia and renal lithiasis treated with lithotripsy 7 years before our observation. She had past resection of intra-abdominal and umbilical endometriosis lesions and elective fallopian tube occlusion at the age of 37 years old. She had history of one caesarean delivery and one-year long peri-menopause phase. She was not under any exogenous systemic estrogen therapy.

She presented with one-week evolution of left low back pain, progressing to 7 in 10 intensity. In the previous 3 months...
she noticed unspecific abdominal volume increase. She exhibited left renal murphy sign and moderate discomfort on left iliac fossa palpation, with no peritoneal irritation signs. She presented microscopic haematuria (43 erythrocytes per high-power field) and left hydronephrosis (10 mm of transverse diameter on proximal ureter) on immediate renal echography, with no visible calculus. Abdominopelvic CT revealed extensive retroperitoneal mass suggestive of lymph node conglomerate involving right common iliac (33x25 mm), left common, internal and external iliac (38x38x110 mm), circum-aortic and infra-renal location, causing left ureter compression (Fig. 1). At this point, the differential diagnosis comprehended retroperitoneal fibrosis, primary or metastatic solid tumors or lymphoproliferative neoplasm. Laparoscopic biopsy was performed. Histology showed replacement of the lymph node parenchyma by spindled cells with fascicular growth and anastomotic branching lymphatic spaces. The spindled cells presented oval nuclei, thin chromatin, eosinophilic or pale cytoplasm and poorly defined cell contours without cytologic atypia or mitotic figures. Immunohistochemistry was performed and showed expression of smooth-muscle actin, desmin, HMB-45 and estrogen receptors and it was negative for Melan-A, compatible with nodal lymphangioleiomyomatosis (Fig. 2). Chest-CT displayed no lung involvement and abdominal CT no renal angiomyolipomas.

Due to the ureteric compression, an elective surgical resection of the lesions was performed with no complications, but no complete excision. She was started on tamoxifen 20 mg a day, with good tolerance. She evolved to menopause around 6 months after diagnosis. She is under yearly thoraco-abdomino-pelvic CT control, last performed 3 years after diagnosis, with no lung involvement, no new abdominal / retroperitoneal lesions and dimensional stability of non-resected lesions.

**Discussion**

The diagnosis of nodal LAM is usually straightforward. Most cases can be identified by hematoxylin and eosin staining due to the particular morphology, but in some settings immunohistochemical tests can be helpful. The gold-standard immunohistochemical diagnostic for LAM is positive immunostaining with HMB-45 antibody. Besides HMB-45, the most commonly used markers in the immunohistochemical diagnosis of LAM are α-smooth muscle actin (SMA), estrogen receptor (ER), and progesterone receptor (PR). Schoolmeester and colleagues examined the expression of HMB45, β-catenin and Melan-A in 18 cases of nodal LAM and found that HMB45 and β-catenin were the more consistently positive markers in nodal LAM (100% of cases) than Melan-A (39%).

Reports of isolated retroperitoneal lymphangioleiomyomatosis are very rare in the literature. As so, its treatment and prognosis are not well established. A study of 22 patients with nodal LAM, found that a diagnosis of nodal LAM preceded development of pulmonary LAM by 1 to 2 years. 11 patients remained asymptomatic and 9 patients had signs or symptoms related solely to abdominopelvic LAM. A relation between size of the affected node (at least one node with more than 10 mm) and subsequent or simultaneous development of pulmonary LAM was suggested. Schoolmeester and colleagues analysed 19 patients with lymph node (pelvic and retroperitoneal) LAM, none had a history of TSC, renal AML or pulmonary LAM. Eighteen patients had surgery for tumours involving the reproductive system and ganglionar involvement.
was an incidental finding. All 18 patients without recurrent or persistent LAM were under 10 mm in greatest dimension.

The difficulty in developing useful therapeutic options for LAM is that the true source of the LAM cell is unknown and the mechanisms that contribute to LAM cell proliferation, metastasis and migration are not fully understood. Positive results are shown on the stabilization of pulmonary function, a reduction of angiofibrolipoma size, and rare reports of affected abdominal and pelvic lymph node size reduction with inhibitors of the mammalian target of rapamycin (mTOR). Sirolimus and everolimus are recommended in pulmonary LAM in the Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines.7 The benefits on extra-pulmonary LAM are not well established.8-10 Estrogen and progesterone receptors are thought to play a role on tumor proliferation. Contradictory results with hormonal therapy, mainly in pulmonary LAM, have been reported in case series.11 The Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines do not recommend its use.7 Inhibition of aromatase to block estrogen synthesis is also conflicting.12 Relative stabilization of the disease course in postmenopausal women with LAM has been described13,14 and may have played an important role in this case. This case reports an atypical evolution, with two >10 mm diameter lesion, with three-year follow-up without pulmonary, renal or other more frequent forms of lymphatic involvement.

**Ethical Disclosures**

Conflicts of interest: The authors have no conflicts of interest to declare.

Financing Support: This work has not received any contribution, grant or scholarship

Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication of data from patients.

Patient Consent: Consent for publication was obtained.

Provenance and Peer Review: Not commissioned; externally peer reviewed.

© Author (es) (ou seu (s) empregador (es)) e Revista SPMI 2020. Reutilização permitida de acordo com CC BY-NC. Nenhuma reutilização comercial.

© Author(s) (or their employer(s)) and SPMI Journal 2020. Re-use permitted under CC BY-NC. No commercial re-use.
REFERENCES


